IgG Subclass Switching In Tumor Infiltrating B Cells and Patient Survival
DOI:
https://doi.org/10.32628/IJSRST25126491Keywords:
Tumor-infiltrating B cells, IgG subclass switching, Class-switch recombination, Cancer immunology, Antibody repertoire, IgG4-mediated immunosuppressionAbstract
Tumor infiltrating B cells have been able to be considered as very important in regulation of anti-tumor immunity, but its prognostic role is always context dependent and also not well understood mechanistically. There is a growing amount of evidence to support that clinical outcome is dependent not on evidence of B cell presence, but on the functional quality of intratumoral antibodies. This review summarizes the existing developments on immunoglobulin G (IgG) subclass switching in tumor-infiltrating B cells and discusses its potential use to improve patient survival in solid malignancies. We describe the molecular and microenvironmental(s) that control the process of class-switch recombination in tumors, and the role that chronic exposure to antigens as well as polarization and crosstalk among tumors and immune responses play in determining IgG subclass bias. Specific focus is placed on the opposite actions between cytotoxic and immunosuppressive activities of a series of IgG subclasses, which have been attributed to immune evasion, reduced effects of action target, and poor clinical outcomes. With the data of bulk, single cell and B-cell receptor repertoire analysis we demonstrate how IgG subclass skewing is associated with prognosis and immunotherapy response of immune checkpoint blockade in various cancer types. Lastly we delve into the emergent approaches to therapy trying to reprogram Tumor-infiltrating B cells or trying to harness the biology of the IgG subclasses to promote anti-tumor immunity. Takit together, the present report places IgG subclass switching as the application functioning biomarker and as an encouraging objective of the subsequent-generation immunotherapies in cancer treatment.
Downloads
References
Harris, R. J., Cheung, A., Ng, J. C., Laddach, R., Chenoweth, A. M., Crescioli, S., ... & Karagiannis, S. N. (2021). Tumor-infiltrating B lymphocyte profiling identifies IgG-biased, clonally expanded prognostic phenotypes in triple-negative breast cancer. Cancer research, 81(16), 4290-4304. https://doi.org/10.1158/0008-5472.CAN-20-3773 DOI: https://doi.org/10.1158/0008-5472.CAN-20-3773
Ni, Z., Xing, D., Zhang, T., Ding, N., Xiang, D., Zhao, Z., ... & Zhou, J. (2021). Tumor-infiltrating B cell is associated with the control of progression of gastric cancer. Immunologic research, 69(1), 43-52. https://doi.org/10.1007/s12026-020-09167-z DOI: https://doi.org/10.1007/s12026-020-09167-z
Toney, N. J., Opdenaker, L. M., Cicek, K., Frerichs, L., Kennington, C. R., Oberly, S., ... & Sims-Mourtada, J. (2022). Tumor-B-cell interactions promote isotype switching to an immunosuppressive IgG4 antibody response through upregulation of IL-10 in triple negative breast cancers. Journal of Translational Medicine, 20(1), 112. https://doi.org/10.1186/s12967-022-03319-5 DOI: https://doi.org/10.1186/s12967-022-03319-5
Carril-Ajuria, L., Desnoyer, A., Meylan, M., Dalban, C., Naigeon, M., Cassard, L., ... & Chaput-Gras, N. (2022). Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study. Journal for immunotherapy of cancer, 10(5), e004885. https://doi.org/10.1136/jitc-2022-004885 DOI: https://doi.org/10.1136/jitc-2022-004885
Yu, J., Song, Y., & Tian, W. (2020). How to select IgG subclasses in developing anti-tumor therapeutic antibodies. Journal of hematology & oncology, 13(1), 45. https://doi.org/10.1186/s13045-020-00876-4 DOI: https://doi.org/10.1186/s13045-020-00876-4
Wang, Z., Cheng, Z., Lu, S., Chard Dunmall, L. S., Wang, J., Guo, Y., & Wang, Y. (2022). Characterization of the intra-tumoral B cell immunoglobulin repertoire is of prognostic value for esophageal squamous cell carcinoma. Frontiers in Immunology, 13, 896627. https://doi.org/10.3389/fimmu.2022.896627 DOI: https://doi.org/10.3389/fimmu.2022.896627
Laumont, C. M., Banville, A. C., Gilardi, M., Hollern, D. P., & Nelson, B. H. (2022). Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities. Nature Reviews Cancer, 22(7), 414-430. https://doi.org/10.1038/s41568-022-00466-1 DOI: https://doi.org/10.1038/s41568-022-00466-1
Kendal, Joseph K., Michael S. Shehata, Serena Y. Lofftus, and Joseph G. Crompton. "Cancer-associated B cells in sarcoma." Cancers 15, no. 3 (2023): 622. https://doi.org/10.3390/cancers15030622 DOI: https://doi.org/10.3390/cancers15030622
Zhang, E., Ding, C., Li, S., Zhou, X., Aikemu, B., Fan, X., ... & Yang, X. (2023). Roles and mechanisms of tumour-infiltrating B cells in human cancer: a new force in immunotherapy. Biomarker Research, 11(1), 28. https://doi.org/10.1186/s40364-023-00460-1 DOI: https://doi.org/10.1186/s40364-023-00460-1
Crescioli, S., Correa, I., Ng, J., Willsmore, Z. N., Laddach, R., Chenoweth, A., ... & Karagiannis, S. N. (2023). B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma. Nature communications, 14(1), 3378. https://doi.org/10.1038/s41467-023-39042-y DOI: https://doi.org/10.1038/s41467-023-39042-y
Kim, S. S., Sumner, W. A., Miyauchi, S., Cohen, E. E., Califano, J. A., & Sharabi, A. B. (2021). Role of B cells in responses to checkpoint blockade immunotherapy and overall survival of cancer patients. Clinical Cancer Research, 27(22), 6075-6082. https://doi.org/10.1158/1078-0432.CCR-21-0697 DOI: https://doi.org/10.1158/1078-0432.CCR-21-0697
Napodano, C., Marino, M., Stefanile, A., Pocino, K., Scatena, R., Gulli, F., ... & Basile, U. (2021). Immunological role of IgG subclasses. Immunological investigations, 50(4), 427-444. https://doi.org/10.1080/08820139.2020.1775643 DOI: https://doi.org/10.1080/08820139.2020.1775643
Pati, S., Mukherjee, S., Dutta, S., Guin, A., Roy, D., Bose, S., ... & Sa, G. (2023). Tumor-associated CD19+ CD39− B regulatory cells deregulate class-switch recombination to suppress antibody responses. Cancer Immunology Research, 11(3), 364-380. https://doi.org/10.1158/2326-6066.CIR-21-1073 DOI: https://doi.org/10.1158/2326-6066.CIR-21-1073
Ye, J., & Lee, P. P. (2022). B cell receptor signaling strength modulates cancer immunity. The Journal of clinical investigation, 132(6). https://doi.org/10.1172/JCI157665 DOI: https://doi.org/10.1172/JCI157665
Rodgers, C. B., Mustard, C. J., McLean, R. T., Hutchison, S., & Pritchard, A. L. (2022). AB‐cell or a key player? The different roles of B‐cells and antibodies in melanoma. Pigment Cell & Melanoma Research, 35(3), 303-319. https://doi.org/10.1111/pcmr.13031 DOI: https://doi.org/10.1111/pcmr.13031
Willsmore, Z. N., Harris, R. J., Crescioli, S., Hussein, K., Kakkassery, H., Thapa, D., ... & Karagiannis, S. N. (2021). B cells in patients with melanoma: implications for treatment with checkpoint inhibitor antibodies. Frontiers in Immunology, 11, 622442. https://doi.org/10.3389/fimmu.2020.622442 DOI: https://doi.org/10.3389/fimmu.2020.622442
Lounici, Y., Le Saux, O., Chemin, G., Wajda, P., Barrin, S., Berthet, J., ... & Dubois, B. (2022). Heterogeneity and Functions of Tumor-Infiltrating Antibody Secreting Cells: Lessons from Breast, Ovarian, and Other Solid Cancers. Cancers, 14(19), 4800. https://doi.org/10.3390/cancers14194800 DOI: https://doi.org/10.3390/cancers14194800
Curcio, C., Mucciolo, G., Roux, C., Brugiapaglia, S., Scagliotti, A., Guadagnin, G., ... & Novelli, F. (2024). PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer. Journal of Experimental & Clinical Cancer Research, 43(1), 157. https://doi.org/10.1186/s13046-024-03080-1 DOI: https://doi.org/10.1186/s13046-024-03080-1
Liu, Y., Liu, Z., Yang, Y., Cui, J., Sun, J., & Liu, Y. (2023). The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer. British Journal of Cancer, 129(7), 1041-1049. https://doi.org/10.1038/s41416-023-02321-y DOI: https://doi.org/10.1038/s41416-023-02321-y
Delvecchio, F. R., Goulart, M. R., Fincham, R. E. A., Bombadieri, M., & Kocher, H. M. (2022). B cells in pancreatic cancer stroma. World Journal of Gastroenterology, 28(11), 1088. https://doi.org/10.3748/wjg.v28.i11.1088 DOI: https://doi.org/10.3748/wjg.v28.i11.1088
Hui, Z., Zhang, J., Ren, Y., Li, X., Yan, C., Yu, W., ... & Ren, X. (2022). Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC). Cell Death & Disease, 13(7), 607. https://doi.org/10.1038/s41419-022-05057-4 DOI: https://doi.org/10.1038/s41419-022-05057-4
Qin, Y., Lu, F., Lyu, K., Chang, A. E., & Li, Q. (2022). Emerging concepts regarding pro-and anti tumor properties of B cells in tumor immunity. Frontiers in Immunology, 13, 881427. https://doi.org/10.3390/cells14010020 DOI: https://doi.org/10.3389/fimmu.2022.881427
Chen, J., Tan, Y., Sun, F., Hou, L., Zhang, C., Ge, T., ... & Zhang, P. (2020). Single-cell transcriptome and antigen-immunoglobin analysis reveals the diversity of B cells in non-small cell lung cancer. Genome biology, 21(1), 152. https://doi.org/10.1186/s13059-020-02064-6 DOI: https://doi.org/10.1186/s13059-020-02064-6
Wang, L., Zhou, Y., Cui, H., Zhuang, X., Cheng, C., Weng, Y., ... & Zhang, W. (2024). IGH repertoire analysis at scale: deciphering the complexity of B cell infiltration and migration in esophageal squamous cell carcinoma. Cancer Gene Therapy, 31(1), 131-147. https://doi.org/10.1038/s41417-023-00689-w DOI: https://doi.org/10.1038/s41417-023-00689-w
Downloads
Published
Issue
Section
License
Copyright (c) 2025 International Journal of Scientific Research in Science and Technology
This work is licensed under a Creative Commons Attribution 4.0 International License.
https://creativecommons.org/licenses/by/4.0
